My Ultimate Sign-in System Made Me Invincible Chapter 552 Observers' Briefing, Preparation For Departure

The acceptance emails arrived, shrouding the world in a hush of focused anticipation. The weeks of rampant speculation and fervent debate ceased, as all attention pivoted to the imminent departure date.

One hundred individuals commenced their final preparations.

The logistical arrangements varied greatly among them. For some, circumstances simplified travel planning. Others required meticulous coordination of medical equipment, detailed documentation of medications, and confirmation of accessible transport from their doorstep to the departure terminal. A few needed assistance with paperwork, as hands that had once managed these tasks were no longer as capable.

A majority opted to bring a companion.

The acceptance email had included provisions for a caretaker – a single, verified individual permitted to travel with the volunteer throughout the mission. While the stated purpose was support, the underlying reason for most families' decisions was more straightforward: who among them did the volunteer trust the most, and who possessed the fortitude to endure whatever lay ahead?

Some families engaged in discussions, albeit gentle ones, regarding this choice. Everyone desired to be the chosen companion, yet everyone understood that only one person could accompany the volunteer.

These selected companions began their own preparations concurrently with the volunteers. What items were essential for a month or more on the moon? What crucial questions needed to be jotted down before they were forgotten? How could they best explain their destination and the reason for their journey to loved ones left behind?

For the majority of the volunteers, the days leading up to departure were a turbulent mix of apprehension and excitement, a rhythm difficult to settle into. They had been informed of what to expect. They had studied the protocols. They had viewed the footage shared by the staff – showcasing the living quarters, the communal areas, and the greenery at the base level – and had attempted to visualize themselves within those spaces.

For the guardian of the volunteer who had remained unresponsive for months, these days unfolded with a different cadence.

They packed with deliberate care, refraining from contemplating the distant future. Each step was taken deliberately, leading them towards the one step that truly mattered.

***

The volunteers were not the sole individuals engaged in preparations. The observers, too, were making their own arrangements, receiving comprehensive briefings from their respective governments and organizations before their own departures.

The World Health Organization's briefing convened in a conference room on the fourth floor of the Regional Office for Europe in Geneva. Through the window, the Palais des Nations was visible, though no one present spared it a glance.

The three-person delegation consisted of Dr. Amara Diallo, a physician from Senegal; Dr. Henrik Sorensen, a Danish specialist in public health; and Counsel Miriam Stein, a Swiss international lawyer tasked with assessing the trial's framework against the existing body of international health law. Her role was to document what aligned, what deviated, and what fell into entirely new categories.

The WHO department heads seated opposite them represented the institution's paramount interests in the trial. The Director of Health Systems was present, as was the lead for the Global Initiative for Emergency and Essential Surgical Care. The head of the Mental Health and Substance Use department, who had been particularly vocal internally regarding the significance of the trial's mental health volunteer cohorts, was also in attendance. Finally, the presence of the Director-General's chief of staff signified that the proceedings in this room carried institutional weight extending beyond individual departments.

The Director of Health Systems commenced the briefing.

"I wish to start by articulating something that should be self-evident, yet requires explicit statement before we proceed further," she declared. "What you are being dispatched to observe is not a clinical trial in any manner that our current frameworks were designed to evaluate. The WHO possesses observer frameworks for pharmaceutical trials, device trials, and surgical procedure assessments. We have protocols for overseeing trials conducted in resource-limited settings, in conflict zones, or under circumstances where standard oversight is compromised. None of these frameworks, in their entirety, are applicable to this situation." She paused meaningfully. "You are proceeding to a facility on the moon to observe a platform technology that is treating one hundred volunteers across every major disease category simultaneously. This initiative is being conducted by an organization that operates entirely outside the scope of any regulatory structures over which we hold authority."

"Your mission consists of three main parts," the Director elaborated. "Firstly, clinical observation, which means recording what you witness on the medical floor within your permitted access, the real-time monitoring data you're granted, and the interactions among staff and volunteers you're allowed to observe. Secondly, geographic equity verification — confirming that the volunteer pool mirrors the distribution commitment outlined in public announcements, specifically the fifteen percent regional cap, and that this distribution exists in reality, not just on paper. Thirdly, framework documentation — noting how the trial's consent procedures, data privacy protocols, and withdrawal rights function in practice compared to what was publicly declared."

She directed her gaze at Stein. "The legal documentation component has the broadest influence. Your written observations become part of the institutional record, the very basis from which any future international health law framework for off-world medical research will be built. This work is unprecedented; you are laying its foundation."

Stein had her copy of the observer framework open, lines marked. She had been contemplating the jurisdictional void since the observer confirmation announcement mentioned the WHO. "We are tasked with evaluating a trial over which we have no authority, conducted in a location beyond any international body's jurisdiction, by an organization that has proven it operates autonomously, disregarding external frameworks." She looked up. "What is the institution's stance on this?"

"The institutional stance," the Director of Health Systems stated, "is that our presence there is more beneficial than our absence, and the documentation we produce holds greater long-term significance than any authority we might theoretically claim but practically cannot enforce." She maintained eye contact with Stein. "We are not feigning influence we do not possess. We are utilizing the access we have been granted."

The head of Mental Health and Substance Use, previously silent, spoke up. "The mental health volunteer categories concern me more than any other trial aspect," she voiced. "Treatment-resistant PTSD. Major depressive disorder. Substance use disorders. These are conditions where outcome measurement is not as objective as, say, spinal cord regeneration. A volunteer walking after a complete spinal cord injury is a clear-cut result. A volunteer reporting improvement in treatment-resistant depression presents a more intricate picture. What does the monitoring data reveal for these cases? How does the system gauge neurological intervention? We are currently unaware, and we won't know until you are in that room witnessing it firsthand."

"This is precisely why your expertise is crucial for this delegation," the Director countered. "Document what you observe without imposing frameworks that are inapplicable. If the monitoring data for a mental health case shows something you cannot interpret with current tools, record exactly what you saw and bring it back. Interpretation will occur here, given time and the complete context."

Dr. Sorensen examined the geographic distribution section of the briefing document. "Regarding volunteers from regions with historically limited healthcare access — when we observe their outcomes, we might be witnessing the initial demonstration of this technology's impact on populations underserved by the current medical system. That observation carries implications far beyond this trial." He set the document down. "I want to ensure the delegation's report adequately emphasizes that significance."

The briefing persisted for two hours. Each department head addressed the trial aspects most pertinent to their responsibilities. Questions were posed and answered when answers were available; the Director remained consistent regarding those that were not.

At its conclusion, she addressed the three delegates across the table.

"You are about to witness advancements the global health community has strived toward for generations," she declared. "Conditions that have defined, diminished, and ended lives across every nation on this planet, now being addressed through methods we could neither design ourselves nor have predicted. You will also witness a framework for medical research existing entirely outside the structures the WHO was established to operate within." She paused. "Both of these realities are true simultaneously. Your task is to observe both with equal discernment and provide an account that is truthful about what this represents — not what we wished it would be, nor what we feared it might become. What it actually is."

She closed the briefing document.